Vector Oncology Revenue and Competitors

Memphis, TN USA

Location

N/A

Total Funding

Research

Industry

Estimated Revenue & Valuation

  • Vector Oncology's estimated annual revenue is currently $6M per year.(i)
  • Vector Oncology's estimated revenue per employee is $91,800

Employee Data

  • Vector Oncology has 65 Employees.(i)

Vector Oncology's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$23M205N/AN/AN/A
#2
$2.1M29N/AN/AN/A
#3
$1.8M254%N/AN/A
#4
$22.2M198-3%N/AN/A
#5
$840.1M58836%N/AN/A
#6
$6M65N/AN/AN/A
#7
$1.9M26-10%N/AN/A
#8
$5.3M58-2%N/AN/A
#9
$20.2M18015%N/AN/A
#10
$5M54-25%N/AN/A
Add Company

What Is Vector Oncology?

Vector Oncology is a leader of oncology specific biopharmaceutical development and commercial outsourcing services. Our novel data repository comprised of aggregated clinical (EMR), patient reported outcomes, genomic, physician notes and billing data powers a broad array of retrospective and prospective HEOR projects that provide an understanding of current practice in oncology care. Vector Oncology also provides comprehensive clinical trial services with specific expertise in supporting and accelerating early phase clinical trials and providing real-world late stage services. All Vector Oncology services are informed by our data repository and medical oncologists who are active members of our team.

keywords:N/A

N/A

Total Funding

65

Number of Employees

$6M

Revenue (est)

N/A

Employee Growth %

N/A

Valuation

N/A

Accelerator

Vector Oncology News

2022-04-20 - Astellas takes $170M hit as DMD gene therapy plan unravels ...

... in 2019— generated preclinical evidence its AAV vector-encoding modified ... Bayer taps another GSK leader to help shape oncology unit.

2022-04-13 - CDx Biomarkers for Oncology Research & Development

Background on oncology companion diagnostics ... Astellas bought for $3 billion in 2019— generated preclinical evidence its AAV vector-encoding modified U7...

2022-03-30 - Viral-vector therapies at scale: Today's challenges and future ...

The past five years have seen viral-vector-based gene therapies become a ... oncology cell therapies) through ex vivo cell modification.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15.8M655%N/A
#2
$12.3M655%N/A
#3
$15M65-13%N/A
#4
$8.8M650%N/A
#5
$15.8M657%N/A